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Abstract
Introduction In this study, we assessed the whole-body
biodistribution and radiation dosimetry of the new gluta-
matergic ligand 11C-ABP688. This ligand binds specifically
to the metabotropic glutamatergic receptor of subtype 5
(mGluR5).
Materials and methods The study included five healthy
male volunteers aged 20–29 years. After intravenous injection
of 240–260 MBq, a series of four to ten whole-body positron
emission tomography/computed tomography scans were
initiated, yielding 60–80 min of data. Residence times were
then calculated in the relevant organs, and the software
packages Mirdose and Olinda were used to calculate the
absorbed radiation dose and the effective dose equivalent.
Results Of the excreted 11C activity at 1 hour, approxi-
mately 80% were eliminated via the hepato-biliary pathway
and 20% through the urinary tract. The absorbed dose (mGy/
MBq) was highest in the liver (1.64 E -2±5.08 E -3),
gallbladder (8.13 E -3±5.6 E -3), and kidneys (7.27 E -3±
2.79 E -3). The effective dose equivalent was 3.68±
0.84 microSv/MBq. Brain uptake in the areas with high
mGluR5 density was 2–3 (SUV). The agreement between the
values obtained from Mirdose and the Olinda was excellent.
Conclusion 11C-ABP688 is a very promising ligand for the
investigation of mGluR5 receptors in humans. Brain uptake
is high and the effective dose equivalent so low that serial
examinations in the same subject seem feasible.
Keywords 11C-ABP688 .Metabotropic glutamate receptor
subtype 5 .Whole-body PET/CT. Dosimetry
Introduction
Since the cloning of the first metabotropic glutamate
receptor (mGlu1) in 1991 [1], seven additional subtypes
of this receptor (mGlu2-8) have been cloned. For the
mGluR5 receptor subtype, based on the wide and consistent
effects of selective noncompetitive allosteric antagonists
such as 2-methyl-6-(phenylethynyl)pyridine in animal
models for anxiety [2, 3], it has been hypothesized that
this receptor could be a valuable target for the treatment of
anxiety-related disorders [4–6]. The development of posi-
tron emission tomography (PET) tracers for the glutama-
tergic receptors proved difficult. Only recently, a series of
PET ligands, allowing the in vivo imaging in rhesus
monkeys, has been described [7]. Recently, we identified
11C-ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-
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2-enone-O-[11C]-methyl-oxime) as a very promising ligand
to investigate mGluR5 [8]. This compound is a highly
selective allosteric antagonist of the mGluR5 receptor in
vitro, and initial studies have demonstrated a high selectiv-
ity for mGluR5 receptors in vivo [8]. The purpose of this
study was to evaluate the whole-body biodistribution and
radiation dosimetry of 11C-ABP688 in humans using
whole-body PET/computed tomography (CT).
Materials and methods
Synthesis of 11C-ABP688
The synthesis of 11C-ABP688 has been described in detail
elsewhere [8]. Briefly, desmethyl ABP688 was reacted with
11C-methyl iodide produced from the GE PET trace system
at 90°C for 5 min. The product was purified by semi-
preparative high-performance liquid chromatography using
a reversed-phase column. Formulation of 11C-ABP688 for
in vivo administration was accomplished using 0.15 M
phosphate buffer and ethanol. The average specific activity
was 232 GBq/μmol (SD±72.56).
Subjects
The study included five healthy male subjects, aged 24.5±
3.2 (range, 20–29 years). All subjects gave their written
informed consent, and the study was approved by the local
ethics committee for radiological research in Zurich.
Positron emission tomography
The subjects were positioned supine in the PET/CT scanner
(Discovery LS and Discovery RX, GE Healthcare, Mil-
waukee). To correct for photon attenuation and for
anatomical reference, a low dose CT scan was performed
before tracer administration. After the injection of 240–
260 MBq 11C-ABP688, a series of four to ten whole-body
scans was initiated. Each scan covered the body from the
head to the knees and consisted of several bed positions
(15 cm field of view). In each bed position, data were
acquired for 1–2 min in 2D mode. Total acquisition time
was 60–80 min. The data were then reconstructed on a
128×128 matrix (slice thickness, 4.25 mm) and corrected
for photon attenuation using the CT scan. Volumes of
interest were placed over different organs using the
software PMOD (http://www.pmod.com) and the CT scan
for anatomical reference, and the time course of radioac-
tivity (Bq/ml) was calculated. Because the output from the
commercial reconstruction software was a decay-corrected
whole-body data set and dosimetry requires the actual, non-
decay-corrected time-course of organ radioactivity, the
decay correction was removed from each time-activity
curve, considering also the actual acquisition time of each
field of view.
Dosimetry
The calculation of dosimetry requires the area under the
time-activity curves, which was calculated as follows: If
possible, a declining monoexponential was fitted to the data
and extrapolated to time-point zero and infinity. If mono-
exponential fitting was not appropriate, the actual data were
numerically integrated to the end point of the scan. After
this time, it was assumed that the activity dropped with the
Fig. 1. Whole-body CT and PET 60–70 min after injection of
260 MBq 11C-ABP688
Fig. 2. Typical tissue time-activity curves of non-decay-corrected 11C
activity
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physical half-time of 11C. As this assumption neglects
clearance of residual activity from the organ, the effective
radiation dose will be somewhat overestimated. The
residence time in the different organs was calculated by
dividing the time integrals by the injected amount of
activity. The mean absorbed dose was subsequently
calculated using the software Mirdose3 [9] and Windows
98 and for comparison with the software Olinda [10] and
Windows 2000.
It is essential to use Mirdose3 with Windows 98 or 95.
The combination of Mirdose3 andWindows XP yields much
lower doses because the S value table is not read correctly. It
shows that only the self-absorption doses (identical source
and target organ) are considered while all other S values
(target organ different from source organs) are zero.
Results
Coronal sections of a typical whole-body PET are demon-
strated in Fig. 1. Most of the 11C activity is found in the
gallbladder and in the bile secreted in the small intestine.
The figure illustrates the primarily hepatobiliary excretion
of the 11C activity. An illustrative set of tissue time-activity
curves is depicted in Fig. 2. In the liver, kidneys, and brain,
the clearance of activity after the initial increase was
Table 1. Residence times (hours) of 11C-ABP688
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Mean SD
Muscles 1.314E-01 9.165E-02 1.317E-01 1.276E-01 1.157E-01 1.196E-01 1.692E-02
Liver 1.434E-01 6.047E-02 8.975E-02 8.431E-02 9.687E-02 9.496E-02 3.034E-02
Bone marrow 2.404E-02 1.514E-02 1.547E-02 1.634E-02 1.759E-02 1.772E-02 3.661E-03
Small intestine 2.067E-02 1.467E-02 1.689E-02 1.907E-02 1.504E-02 1.727E-02 2.582E-03
Brain 1.845E-02 1.293E-02 1.679E-02 1.591E-02 1.259E-02 1.533E-02 2.524E-03
Kidney 1.043E-02 4.181E-03 6.838E-03 3.693E-03 8.490E-03 6.726E-03 2.851E-03
Urinary bladder 8.220E-03 1.676E-03 5.244E-03 3.364E-03 8.135E-03 5.328E-03 2.892E-03
Lung 2.796E-03 2.235E-03 2.829E-03 2.363E-03 2.925E-03 2.630E-03 3.089E-04
Gallbladder 5.118E-04 1.633E-03 3.241E-03 7.038E-05 6.041E-03 2.299E-03 2.423E-03
Heartwall 2.283E-03 1.588E-03 2.055E-03 1.959E-03 1.826E-03 1.942E-03 2.590E-04
Pancreas 1.414E-03 5.517E-04 1.199E-03 1.243E-03 1.611E-03 1.204E-03 3.990E-04
Spleen 1.335E-03 6.712E-04 1.320E-03 9.744E-04 1.155E-03 1.091E-03 2.765E-04
Testes 2.120E-04 1.825E-04 2.381E-04 1.360E-04 2.057E-04 1.948E-04 3.839E-05
Thyroid 1.873E-04 1.100E-04 1.210E-04 1.426E-04 1.301E-04 1.382E-04 2.994E-05
Table 2. Absorbed dose estimates (mGy/MBq) and effective dose equivalent (mSv/MBq) for 11C-ABP688
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Mean MIRD SD MIRD Mean Olinda SD Olinda
Liver 2.44E-02 1.05E-02 1.56E-02 1.45E-02 1.68E-02 1.64E-02 5.08E-03 1.64E-02 5.12E-03
Gallbladder wall 5.17E-03 5.61E-03 1.02E-02 2.75E-03 1.69E-02 8.13E-03 5.60E-03 8.12E-03 5.55E-03
Kidneys 1.10E-02 4.64E-03 7.32E-03 4.50E-03 8.87E-03 7.27E-03 2.79E-03 7.27E-03 2.79E-03
Small intestine 7.20E-03 4.94E-03 5.86E-03 6.40E-03 5.34E-03 5.95E-03 8.90E-04 5.94E-03 8.87E-04
Pancreas 5.90E-03 2.58E-03 4.82E-03 4.77E-03 6.01E-03 4.82E-03 1.38E-03 4.85E-03 1.39E-03
Urinary bladder wall 6.26E-03 6.08E-03 4.18E-03 2.93E-03 6.09E-03 5.11E-03 1.49E-03 4.23E-03 2.01E-03
Brain 4.33E-03 3.05E-03 3.95E-03 3.74E-03 2.99E-03 3.61E-03 5.81E-04 3.62E-03 5.90E-04
Red marrow 3.46E-03 2.12E-03 2.40E-03 2.44E-03 2.60E-03 2.60E-03 5.09E-04 2.61E-03 5.14E-04
Heart wall 3.17E-03 2.00E-03 2.67E-03 2.54E-03 2.51E-03 2.58E-03 4.18E-04 2.59E-03 4.33E-04
Thyroid 2.84E-03 1.70E-03 1.98E-03 2.20E-03 2.04E-03 2.15E-03 4.25E-04 2.14E-03 4.09E-04
Adrenals 2.49E-03 1.24E-03 1.79E-03 1.64E-03 1.89E-03 1.81E-03 4.54E-04 1.83E-03 4.65E-04
Muscle 1.95E-03 1.26E-03 1.81E-03 1.73E-03 1.67E-03 1.68E-03 2.59E-04 1.69E-03 2.64E-04
Testes 1.80E-03 1.47E-03 2.01E-03 1.35E-03 1.80E-03 1.69E-03 2.69E-04 1.68E-03 2.82E-04
ULI wall 2.03E-03 1.22E-03 1.62E-03 1.58E-03 1.63E-03 1.62E-03 2.87E-04 1.62E-03 2.91E-04
Lungs 1.21E-03 1.19E-03 1.62E-03 1.45E-03 1.65E-03 1.42E-03 2.18E-04 1.57E-03 2.69E-04
Stomach 1.29E-03 7.16E-04 1.03E-03 9.61E-04 1.05E-03 1.01E-03 2.06E-04 1.03E-03 2.15E-04
LLI wall 1.13E-03 7.03E-04 9.55E-04 9.38E-04 9.32E-04 9.32E-04 1.52E-04 9.33E-04 1.52E-04
Effective dose equivalent 4.53E-03 2.63E-03 3.79E-03 3.02E-03 4.42E-03 3.68E-03 8.40E-04 3.70E-03 8.69E-04
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adequately fitted by a decaying monoexponential. In the
gall bladder, the small intestine, and the urinary bladder, the
time-course was more protracted. Of the excreted 11C
activity at 1 h, approximately 80% were eliminated via the
hepato-biliary pathway and 20% through the urinary tract.
The residence times are summarized in Table 1. Because of
the large mass, it was largest in the muscles, followed by
liver, bone marrow, and small intestine. The smallest values
were found in the testes and the thyroid gland. The mean
absorbed dose in the various organs is reported in Table 2.
The highest absorbed dose was present in the liver,
followed by gall bladder wall, kidneys, and small intestine.
The agreement between the values calculated with the
softwares Mirdose3 and Olinda in the different organs was,
in general, excellent. A small discrepancy was observed in
the urinary bladder (Olinda, 17% lower) and the lungs
(Olinda, 10% larger). Nevertheless, the mean effective dose
equivalent was almost identical. The distribution of 11C-
ABP688 in the brain is demonstrated in Fig. 3a. High tracer
uptake is found in the cortex, especially in the mediotem-
poral area; less uptake was present in the thalamus, and the
lowest tracer accumulation was present in the cerebellum.
Corresponding tissue time-activity curves are illustrated in
Fig. 3b.
Discussion
The presented data demonstrate a promising distribution
and kinetics of 11C-ABP688 for the evaluation of mGluR5.
Brain uptake is high, which results in high-quality images
and good statistics for quantification. The pattern of tracer
distribution in the brain is similar to the one described in
our recent animal [8] and human study [11].
The study demonstrates that the main route of elimination
of the tracer is the hepato-biliary pathway followed by the
urinary tract. This is not surprising given the lipophilicity of
11C-ABP688. As a consequence, the liver and the gall
bladder are the organs with the highest absorbed dose.
One possible error in the dosimetry could result from the
monoexponential fitting, which was applied in this study.
Especially in organs with a low retention of the tracer, there
will be an early perfusion phase that is missed in whole-
body scanning. To estimate this error, we assumed that this
perfusion phase would add 20% to the residence times of
myocardium, kidney, liver, lung, and bone marrow. The
recalculation then revealed, that this 20% increase would
add only 11% to the mean effective dose equivalent (4.10E-
03±9.80E-04 vs 3.70E-03±8.69E-04 mSv/MBq).
Concerning radiation protection, 11C-ABP688 compares
favorably with other receptor tracers. For example, the
effective dose equivalent is lower than the 6.7 microSv/
MBq reported for 11C-raclopride, a marker to measure
dopaminergic D2 receptors [12] and considerably lower
than the 19 microSv/Mbq estimated for the tracer 18F-
Fluoro-A-85380, a candidate for the investigation of nico-
tinic receptors [13]. The injected amount of about 250 MBq
11C-ABP688 resulted in an effective dose equivalent of
0.9–1.1 mSv. This low value allows multiple serial exa-
minations of the same subject. For instance, an upper limit
of the radiation burden of 5 mSv would allow the injection
of 1,000 Mbq 11C-ABP688, including the addition 11%
increase caused by the possible underestimation because of
monoexponential fitting. On modern scanners operated in
3D mode, 200 Mbq are sufficient for a single scan, meaning
that one subject could be investigated on five different
occasions. This opens the possibility of very efficient
interventional studies, for instance, receptor occupancy
studies with new drugs aimed at interfering with the
mGluR5 receptor.
Whole-body PET has been recently used for dosimetry
studies in humans by several groups [12–16]. This became
possible only recently with the latest generation of scanners
that allow whole-body scanning with adequate temporal
resolution. In the past, most dosimetry calculations were
done with the software Mirdose3. Because of incompati-
bilities with newer operating systems, the code was
rewritten and was made available as Olinda [10], which
may become more widespread in the future. The excellent
Fig. 3. 11C-ABP688 distribution in the brain 40–50 min after
injections (a) and decay-corrected tissue time-activity curves of
several brain areas (b). The data were taken from another study in
which the brain distribution of 11C-ABP688 was evaluated [11]
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agreement of the values calculated with both programs
indicates that they are interchangeable.
Conclusion
11C-ABP688 is a very promising ligand for the investiga-
tion of mGluR5 receptors in humans. Brain uptake is high
and the effective dose equivalent so low that serial
examinations in the same subject seem feasible.
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